Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maria José Temido"'
Autor:
Maria José Temido, Rui Caetano Oliveira, Andrea Silva, Guilherme Nogueira Fontinha, Sandra Maria Fernandes Lopes, Pedro Figueiredo, Francisco Portela
Publikováno v:
Gastrointestinal Disorders, Vol 5, Iss 4, Pp 419-430 (2023)
Introduction: Many patients with Crohn’s Disease (CD) require surgical resection during their lifetime. Nevertheless, postoperative recurrence (POR) is common. Risk factors for POR are still yet to be completely established, but some prognostic fac
Externí odkaz:
https://doaj.org/article/085a31e0e5d947c3b82625679b627b60
Autor:
Maria José Temido, Dara Mbanze, Nuno Almeida, Bárbara Oliveiros, Elisa Gravito-Soares, Pedro Figueiredo
Publikováno v:
Annals of Clinical Microbiology and Antimicrobials, Vol 22, Iss 1, Pp 1-10 (2023)
Abstract Introduction Hybrid therapy (HT) is a non-bismuth quadruple therapy created to surpass Helicobacter pylori’s (H. pylori) resistance rates to antibiotics. HT has excellent eradication rates, as well as a very good compliance and safety prof
Externí odkaz:
https://doaj.org/article/5fc69afd9664434293dbdefe72c87003
Autor:
João Estorninho, Pedro Patrão, Maria José Temido, David Perdigoto, Pedro Figueiredo, Paulo Donato
Publikováno v:
GE: Portuguese Journal of Gastroenterology, Pp 1-6 (2022)
Introduction: Parastomal variceal bleeding (PVB) is a recognized complication of ostomized patients in the presence of portal hypertension. However, since there are few reported cases, a therapeutic algorithm has not yet been established. Case Presen
Externí odkaz:
https://doaj.org/article/00b2d4c3977742cc8e7ed344c7cf20bd
Autor:
Joana Revés, André Mascarenhas, Maria José Temido, Bárbara Morão, Catarina Neto Nascimento, Ana Rita Franco, Raquel R Mendes, Carolina Palmela, Cristina Chagas, Pedro Narra Figueiredo, Luísa Glória, Francisco Portela, Joana Torres
Publikováno v:
Journal of Crohn's and Colitis.
Background Early biological therapy within the first 18-24 months after diagnosis is associated with improved clinical outcomes in Crohn’s disease (CD). However, the definition of the best time to initiate biological therapy remains unclear. We aim
Autor:
César Carvalho, Luís Pinto Ferreira, Beatriz Costa, Marco Serôdio, Paulo Teixeira, José Guilherme Tralhão, Henrique Alexandrino, Maria Augusta Cipriano, Rui Caetano Oliveira, Maria José Temido, Ricardo Martins, Eva Santos
Publikováno v:
Cancer Management and Research
Maria José Temido,1,2,* Rui Caetano Oliveira,3– 6,* Ricardo Martins,2,4,5,7 Marco Serôdio,2,7 Beatriz Costa,2,5,7 César Carvalho,7 Eva Santos,2,7 Luís Ferreira,7 Paulo Teixeira,3,8 Maria Augusta Cipriano,3 José Guilherme Tralhão,2,4,5,7 Henri
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de Medicina Introduction: Hepatectomy (Hp) might have a definitive role in the treatment of gastric cancer liver metastases (GCLM), due to poor outcomes of other therapies. How
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1271::419e1a0d0e46fe026278b30096de81cf
https://hdl.handle.net/10316/82542
https://hdl.handle.net/10316/82542
Publikováno v:
CIÊNCIAVITAE
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::816fc8ff97b5a959e13b3082272c39a2
http://hdl.handle.net/10316/82542
http://hdl.handle.net/10316/82542